Patient description: A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.

Clinical trial eligibility criteria: eligible ages (years): 20.0-85.0,  Acute Ischemic Stroke Patients with neurological disorders caused by blood vessel occlusion associated with acute cerebral infarction 2. Patients who can receive treatment within 8 hours after onset of symptoms of acute cerebral infarction 3. Patients in whom intravenous administration of t-PA is not indicated or reperfusion cannot be achieved by intravenous t-PA administration 4. Patients who have accessible occlusion of the middle cerebral artery (M1 or M2 to 3), basilar artery, vertebral artery, posterior cerebral artery (P1 or P2), anterior cerebral artery (A1 to 2), or intracranial internal carotid artery (pre-procedure TICI score, 0 or 1) as determined by angiography 5. Patients with an NIHSS score of 8 to 30 6. Patients with an mRS score of 0 to 2 before onset 7. Patients aged between 20 and 85 years (at the time of informed consent) 8. Patients who are able to provide written consent (signature) or whose legally acceptable representative (a person with parental authority, spouse, guardian, and an individual legally responsible for his/her custody) can provide written consent (signature)  Patients who manifest the following Carotid artery dissection Vasculitis An angulated vessel, making it difficult to guide an investigational device Significant (>50%) stenosis, making it difficult to guide an investigational device Acute intracranial hemorrhage Mass lesion or intracranial tumor Widespread early ischemic changes revealed by CT or MRI 2. Patients who have two or more different major cerebrovascular occlusions requiring treatment 3. Patients with an allergy to contrast agents or who cannot receive them or those who have a serious metal allergy 4. Patients who received heparin within 48 hours and have Partial Thromboplastin Time (PTT)/Activated Partial Thromboplastin Time (APTT) > twice the upper limit of normal 5. Patients with known bleeding tendencies or coagulation deficiency or who have received oral anticoagulants (such as warfarin), and who have (PT-) International Normalized Ratio (INR) >3 6. Patients with platelet count <30,000 /mm3 7. Patients with blood glucose levels <50 mg/dL 8. Patients with uncontrolled hypertension (systolic BP >185 mmHg and diastolic BP >110 mmHg) 9. Patients with expected life expectancy <90 days 10. Female patients who are pregnant or breast feeding 11. Patients who are participating in clinical trials of drugs or medical devices 12. Patients disqualified from participation in the study by the investigator (sub-investigator) due to reasons other than the above